Method for determining degree of modified potency of bipathic medicament

专利摘要:
The invention comprises a method for determining degree of modified potency of a bipathic medicament. A bipathic medicine is a medicament comprising a therapeutic component and a homeopathic component, wherein the homeopathic component has some physical, chemical or biological affect on the therapeutic component and/or the pharmacological efficacy thereof. An analytical measurement of at least one characteristic parameter of the therapeutic form is made prior to its interaction with the activated-potentiated form. The same analytical measurement(s) are made and after interaction between the therapeutic and activated- potentiated forms. This data is used to confirm the presence of any modified potency is caused by the presence of molecular form in the activated-potentiated form. Further, the claimed analytical measurement of at least one characteristic parameter of the therapeutic form prior to its interaction with the activated-potentiated form and again after such interaction serves to quantify the degree of modifying potency associated with the activated- potentiated form in relative dimensionless activity units (release activity).
公开号:ES2560897A2
申请号:ES201590109
申请日:2014-03-18
公开日:2016-02-23
发明作者:Oleg Iliich Epshtein
申请人:Oleg Iliich Epshtein；
IPC主号:

专利说明:

5
10
fifteen
twenty
25
30
35
DESCRIPTION
Method for determining the intensity of the activity of modification of bipatic drugs
This application claims the priority of Russian Patent Application No. 2013111961, filed on March 18, 2013, which is incorporated herein by reference in its entirety.
Countryside
The present invention relates to the field of medicine, specifically to the pharmaceutical field. The invention is used to determine the modified potency of drugs, especially bipathic drugs, in at least one component thereof that is prepared in accordance with homeopathic techniques, in a reliable and reproducible manner.
Background
Activated-enhanced form
Medications prepared according to homeopathic techniques include those that are prepared by homeopathic potentiation, also referred to as activation, through multiple consecutive dilutions in a carrier (water or water-alcohol solvent) - therefore decreasing the concentration - in combination with the agitation of each consecutive dilution. See, for example, RU 2191601 C1; RU 2192888 C1; RU 2332236 C1 (English version found in EP 2 123 300); and RU 2438707 C2 (U.S. Patent Publication 2011/0008452). The result of the preparation by homeopathic potentiation is a medication that contains low or very low doses of the initial medication; The dilution can continue to approach or exceed 1 mole of carrier per molecule of the initial drug in the molecular form, bearing in mind that the total number of molecules per mole is given by Avogadro's number (6.022 x 1023 mol-1). The term molecular form is defined below. In the context of a solid, the dilution is referred to as trituration. Through homeopathic techniques the carrier can obtain modifying power, which is manifested in his ability to alter the physical, chemical and / or biological properties of the starting substance when treated by said activated-enhanced form (RU 2161955 C1) .
5
10
fifteen
twenty
25
30
35
The term "molecular form" is used to denote one or more molecules of a particular chemical substance. In this way, the molecular form of aspirin can be a single molecule of acetylsalicylic acid; 1 mole of aspirin in molecular form consists of 6.022 x 1023 molecules of acetylsalicylic acid and weighs 180,157 grams.
The term "activated-potentiated form" is used to denote a homeopathic potentiation product of an initial solution containing a molecular form of a substance. In other words, a solution containing the molecular form of a substance, for example, an antibody or Specific organic molecule is subjected to repeated consecutive dilution and multiple vertical shaking of each solution obtained according to homeopathic techniques.The preferred diluent, often referred to as the carrier, is water or a mixture of water-alcoholic alcohol. the molecular form in the initial carrier is in a range from about 0.5 to about 5.0 mg / ml The activated-enhanced form can be prepared from an initial solution by means of homeopathic potentiation, preferably using the method of reduction of the proportional concentration by serial dilution of 1 part of each preceding solution. or, 1 part of the initial solution is mixed with 99 parts (for centesimal dilution) of the carrier and subjected to external impact. Preferably, the external impact involves multiple vertical shaking (dynamization) of each dilution. This results in the creation of the 1st centesimal dilution, denoted C1. The 2nd centesimal dilution (C2) is prepared by mixing 1 part of the 1st centesimal dilution C1 with 99 parts of the carrier. This procedure is repeated 10 more times to prepare the 12th C12 centesimal dilution. Usually separate containers are used for each subsequent dilution up to the required dilution factor. Similar procedures with the relevant dilution factor are carried out to obtain, for example, dilutions C30, C50 and C200. This method is well accepted in the art of homeopathy. See, for example, V. Schwabe "Homeophatic medicines", M., 1967, p. 14-29, incorporated herein by reference for the established purposes. C12, C30, and C200 represent dilutions of the primary matrix solution ( mother tincture) of antibodies 10012, 10030 and 100200 times, respectively.
Preferred potentiated activated forms are often a mixture of various centesimal dilutions of the same molecular form. For example, a mixture of dilutions C12, C30, and C50 or dilutions C12, C30 and C200. When the mixture of several homeopathic dilutions is used, each component of the composition, for example, C12, C30, C50, C200, is prepared separately according to the described procedure
3
5
10
fifteen
twenty
25
30
35
Line before before the penultimate dilution is obtained, that is, up to C11, C29 and C199 respectively, and then a part of each component is added in a container according to the composition of the mixture and mixed with the required amount of the carrier , that is, 97 parts per centesimal dilution.
Examples of homeopathic potentiation are described in U.S. Pat. Nos. 7,572,441 and 7,582,294, which are incorporated herein by reference in their entirety and for the established purposes. The term "activated-potentiated form" and the term "ultra low dose" are completely conceived as supportive and are primarily synonymous with each other.
Homeopathic bipatia
The U.S. Patent No. 8,178,498 describes the concept of bipathic medicinal forms. Bipathic medicinal preparations combine the therapeutic values of a medicinal substance in therapeutic doses and a chemically activated-potentiated preparation homogenous with the medicinal substance but different in the mechanism of action in the organism. In other words, the described bipatic medicinal preparation combines the molecular form of a medicinal substance in approximately its standard concentration and an activated-potentiated form that is derived from the same molecular form but which has its molecular form present, if at all, in very concentrated concentrations. low. The standard dose and the activated-potentiated form, whether combined or administered approximately simultaneously, show that they promote biological activation and induce positive morphological and functional changes in the form of "systemic adaptation" responsible for the increased therapeutic efficiency of the substance. Active medicinal product with reduced risk of individual reactions in patients and unwanted side effects or adverse effects.
Moreover, the simultaneous "bipatic" administration of the medicinal substance in therapeutic dose and activated-potentiated form, in accordance with US Patent No. 8,178,498: (1) allows lower conventional doses of the substance, (2) prevents habituation due to enzymatic induction, and (3) avoids overdose due to neutralization of negative energies and stimulation of certain organs and of the whole. The U.S. Patent No. 8,178,498 is incorporated herein in its entirety as a reference and for the established purposes.
Qualitative / quantitative evaluation of medications
5
10
fifteen
twenty
25
30
35
As is known in the art, for example, RU 2181890 C1, is a method for determining the biological activity of a substance. The activity is represented by a relationship between the rate of enzymatic response to a test sample before and after adding the substance. A "concentration of optimal substance in a sample" is determined in vitro. However, this method is not suitable for determining the potency of drugs prepared according to homeopathic techniques.
As is known in the art, it is the method for determining the homeopathic potency of the drug by applying linearly polarized coherent optical radiation to an activated drug present in a constant magnetic field. The diffused transmitted radiation is measured using the time-related accumulation of the values of its polarized component intensity in the optical deviation mode from different points of the test medium. The analysis is performed to calculate the frequency spectrum of very low fluctuations of the transmitted intensity and the data is compared with a standard specimen. See, for example, RU 2112976 C1.
The method for the qualitative determination of homeopathic medicine or the activated-potentiated form is also known. The method includes the treatment of a means for testing with a standard specimen and the recording of physical and chemical parameter alterations. A set of known substances is used whose structure and / or composition are approximately similar or similar to those of the determined homeopathic medicine or to those of the potentiated substance form as well as the structure and / or composition of the antibodies for these known substances. The identification of homeopathic medicine or potentiated substance form will be based on the known substance, whose reaction with the appropriate antibody when homeopathic medicine is introduced or form of enhanced substance in the reaction medium is accompanied by alterations that are recorded using the methods immunoqulmic analysts based on the antigen-antibody reaction (RU 2195648 C2).
The prior art methods, however, do not provide reliable and reproducible qualitative and quantitative determination of the identity and potency of the drug associated with an activated-potentiated form. This includes activated medications prepared according to the homeopathic techniques described above.
Summary of the invention
5
10
fifteen
twenty
25
30
35
A method for determining the activity of the activated-enhanced form of a substance, said method comprising: providing an activated-enhanced form of a substance, ensuring the absence of the molecular form of the substance in said activated-enhanced form, providing a form molecular of said substance, measuring at least one physical, chemical or biological parameter (A) of said molecular form of said substance using a suitable analytical method, treating said molecular form of said substance with said activated-enhanced form of said substance, and measuring said at least one physical, chemical or biological (Am) parameter of said treated molecular form of said substance using said analytical method, wherein said activity of said activated-enhanced form of said substance is the degree of difference between A and Am .
The method described above lines, further comprising expressing said activity of said activated-enhanced form of said substance in relative units (X) according to formula X = C (A-AM) / A.
The method described above lines, further comprising i) treating a molecular form of a different substance with said activated-enhanced form of the first substance, ii) measuring said at least one physical, chemical or biological parameter (B) of said molecular form of said different substance with said analytical method, iii) measuring said at least one physical, chemical or biological parameter (Bm) of said treated molecular form of said different substance using said analytical method to determine the specificity of said method, wherein said The method is considered specific when said at least one physical, chemical or biological parameter changes statistically significantly for A-Am and does not change statistically significantly for B-Bm.
The method described above, where said analytical method is High Performance Liquid Chromatograph.
The method described above, wherein said analytical method is immunoenzymatic analysis.
The method described above, where said analytical method is Nuclear Magnetic Resonance.
The method described above, wherein said step of ensuring the absence of the molecular form of the substance comprises the removal of the molecular form of said substance.
5
10
fifteen
twenty
25
30
35
The method described above lines, wherein said substance is an antibody.
The method described above lines, wherein said antibody is a polyclonal antibody.
The method described above lines, wherein said substance is a small organic molecule.
The method described above lines, wherein said activated-enhanced form is a liquid.
The method described above lines, wherein said activated-enhanced form is impregnated in a solid carrier.
Brief description of the figures
Figure 1 shows the superposition of the NMR spectra of Ab for IFN-gamma + AC and Ab for IFN-gamma + purified water.
Detailed description of the invention
The present invention is defined with reference to the appended claims. With respect to the claims, relevant definitions have been provided above and additional definitions are provided at this point.
The term "antibody" as used herein means an immunoglobulin that specifically binds to, and is therefore defined as complementary to, a particular spatial and polar organization of another molecule. Antibodies as set forth in the claims may include a complete immunoglobulin or fragment thereof, may be natural, polyclonal or monoclonal, and may include various classes and isotypes, such as IgA, IgD, IgE, IgG 1, IgG2a, IgG2b and IgG3, IgM, etc. Fragments thereof may include Fab, Fv and F (ab ') 2, Fab', and the like. The singular "antibody" includes the plural "antibodies."
The terms "activated-potentiated form" or "enhanced form" are used to denote a homeopathic potentiation product of any initial solution containing a molecular form of a substance, for example, an antibody. Examples of homeopathic antibody potentiation are described in U.S. Pat. Nos. 7,572,441 and 7,582,294, which are incorporated herein by reference in their entirety and for
5
10
fifteen
twenty
25
30
35
stated purpose. An antibody is in the "activated-enhanced" or "enhanced" form when three factors are present. First, the "activated-potentiated" form of the antibody is a product of a preparation process well accepted in the art of homeopathy. Second, the "activated-potentiated" form of the antibody must have biological activity determined by methods well accepted in modern pharmacology. Third, the biological activity exhibited by the "activated-enhanced" form of the antibody cannot be explained by the presence of the molecular form of the antibody in the final product of the homeopathic process.
There has been a considerable amount of controversy regarding the homeopathic treatment of human subjects. While the present invention relies on accepted homeopathic processes to obtain the "activated-potentiated" form of a substance, that is, molecular form, it is not based solely on homeopathy in human subjects for evidence of activity. In particular to the molecular forms consisting of antibodies, it has been surprisingly discovered by the inventor of the present application and widely demonstrated in accepted pharmacological models that the solvent finally obtained from the consecutive multiple dilution of a starting molecular form of an antibody has definitive activity not related to the presence of traces of the molecular form of the antibody in the target dilution. Also, the claimed "activated-potentiated" form of the antibody encompasses only solid solutions or preparations whose biological activity cannot be explained by the presence of the molecular form of the remaining antibody of the initial, starting solution. In other words, while it is contemplated that the "activated-potentiated" form of the antibody may contain traces of the initial molecular form of the antibody, a person skilled in the art cannot attribute the biological activity observed in the accepted pharmacological models to the form Molecular remnant of the antibody with some degree of plausibility due to extremely low concentrations of the molecular form of the remaining antibody after consecutive dilutions. While the invention is not limited by any specific theory, the biological activity of the "activated-enhanced" form of the antibodies of the present invention is not attributable to the initial molecular form of the antibody. The "activated-potentiated" form of the antibody in a liquid or solid carrier in which the concentration of the molecular form of the antibody is below the detection limit of accepted analytical techniques, such as capillary electrophoresis and High Chromatography, is preferred. Performance. Particularly preferred is the "activated-enhanced" form of the antibody in liquid or solid form in which the concentration of the molecular form of the antibody is below the Number of
8
5
10
fifteen
twenty
25
30
35
Avogadro, that is, 1 molecule of the molecular form per 6.022 x 1023 carrier molecules.
The pharmaceutical composition of the invention expands the arsenal of preparations available for the treatment of infectious disease prophylaxis, including bacterial infections and acute and chronic viral infections.
The pharmaceutical combination composition according to this aspect of the invention may be in liquid form or in solid form. The preferred method for the preparation of the activated-potentiated component of the combination drug according to the present invention is the use of the mixture of three aqueous-alcoholic dilutions of the primary matrix solution of the diluted antibodies 10012, 10030 and 10050 times , respectively, which is equivalent to the C12, C30, and C50 centesimal homeopathic dilutions or diluted 10012, 10030 and 100200 times, respectively, which is equivalent to the C12, C30 and C200 centesimal homeopathic dilutions. To prepare a solid dosage form, a solid carrier is treated with the desired dilution obtained by the homeopathic process. To obtain a solid unit dosage form of the combination of the invention, the carrier mass is impregnated with each of the dilutions. Both impregnation orders are suitable for preparing the dosage form of the desired combination.
In the event that the activated-potentiated form included in the pharmaceutical composition is prepared from an initial molecular form of the antibody, it is thus carried out in a process accepted in the art of homeopathy. The starter antibodies can be monoclonal or polyclonal antibodies prepared according to known processes, for example, as described in Immunotechniques, G. Frimel, M., "Meditsyna", 1987, p. 9-33; "Hum. Antibodies Monoclonal and recombinant antibodies, 30 years after ”by Laffly E., Sodoyer R. - 2005 - Volume 14. - N 1-2. P.33-55, both incorporated herein by reference.
Monoclonal antibodies can be obtained, for example, by means of hybridoma technology. The initial stage of the process includes immunization based on the principles already developed in the course of the preparation of polyclonal antisera. Additional work stages involve the production of hybrid cells generating clones of antibodies with identical specificity. Its separate isolation is carried out using the same methods as in the case of the preparation of polyclonal antisera.
5
10
fifteen
twenty
25
30
35
Polyclonal antibodies can be obtained by active immunization of animals. For this purpose, for example, suitable animals (for example, rabbits) receive a series of injections of the appropriate antigen (cytokine and receptor). The animal's immune system generates the corresponding antibodies, which are collected from the animals in a known way. This procedure allows the preparation of a serum rich in monospecific antibodies.
If desired, the serum containing antibodies can be purified, for example using afln chromatography, salt precipitation fractionation, or ion exchange chromatography. The resulting purified antibody-enriched serum may be used as a starting material for the preparation of the activated-potentiated form of the antibodies. The preferred concentration of the initial solution resulting from antibody in the solvent, preferably water or a mixture of water-alcoholic alcohol, is in a range from about 0.5 to about 5.0 mg / ml.
An exemplary procedure for the preparation of a molecular form consisting of polyclonal antibodies to CD4 receptor can be described as follows. In 7-9 days before taking the blood sample, 1-3 intravenous injections of the desired antigen are made to the rabbits to increase the level of polyclonal antibodies in the rabbit's bloodstream. After immunization, blood samples are taken to test the antibody level. Generally, the maximum level of immune reaction of the soluble antigen is reached within 40 to 60 days after the first injection of the antigen. After completion of the first immunization cycle, rabbits have a 30-day rehabilitation period, after which re-immunization is performed with another 1-3 intravenous injections. To obtain the antiserum containing the desired antibodies, the immunized rabbit blood is collected from the rabbits and placed in a 50 ml centrifugation tube. The product clots formed on the sides of the tube are removed with a wooden spatula, and a rod is placed in the clot in the center of the tube. The blood is then placed in a refrigerator for one night at the temperature of approximately 40 ° C. The next day, the clot in the spatula is removed, and the remaining fluid is centrifuged for 10 min at 13,000 rotations per minute. The supernatant fluid is the target antiserum. The antiserum obtained is usually yellow. 20% NaN3 (concentration by weight) is added to the antiserum for a final concentration of 0.02% and stored before use in the frozen state at the temperature of -20 ° C or without NaN3 at the temperature of -70 ° C. To separate antibodies
5
10
fifteen
twenty
25
30
35
Aim for interferon gamma of the antiserum, the following solid phase absorption sequence is suitable:
- 10 ml of the rabbit antiserum is diluted twice with 0.15 M NaCl, after which 6.26g of Na2SO4 is added, mixed and incubated for 12-16 hours at 4 ° C. The sediment is removed by centrifugation, diluted in 10 ml of phosphate buffer solution and dialyzed against the same buffer solution overnight at room temperature. After the sediment is removed, the solution is applied to a balanced DEAE-cellulose column by means of the phosphate buffer solution. The antibody fraction is determined by measuring the optical density of the eluate at 280 nm.
- The isolated crude antibodies are purified using the afln chromatography method by binding the antibodies obtained to the CD4 antigen located in the insoluble matrix of the chromatography media, with subsequent elution by means of aqueous concentrated salt solutions.
- The resulting buffer solution is used as the initial solution for the homeopathic dilution process that is used to prepare the activated-potentiated form of the antibodies. The preferred concentration of the initial matrix solution of polyclonal rabbit antibodies of purified antigen for CD4 receptor is 0.5 to 5.0 mg / ml, preferably 2.0 to 3.0 mg / ml.
Preferably, the pharmaceutical composition in the solid unit dosage form is prepared from pharmaceutically acceptable carrier granules that were previously saturated with the aqueous or aqueous-alcoholic dilutions of the activated-enhanced form of antibody CD4 receptor . The solid dosage form may be in any form known in the art of pharmaceuticals, including a tablet, a capsule, a tablet and others. As an inactive pharmaceutical ingredient, glucose, sucrose, maltose, starch, isomalt, isomalt and other mono-, oligo- and polycarbons which are used in the manufacture of pharmaceutical products can be used! as well as technological mixtures of the aforementioned inactive pharmaceutical ingredients with other pharmaceutically acceptable excipients, for example isomalt, crospovidone, sodium cyclamate, sodium saccharin, anhydrous citric acid, etc.), including lubricants, disintegrants, binders and coloring agents. Preferred carriers are lactose and isomalt. The pharmaceutical dosage form may also include
5
10
fifteen
twenty
25
30
35
standard pharmaceutical excipients, for example, microcrystalline cellulose, magnesium stearate and citric acid.
To prepare the oral solid form, 100 to 300 pm of lactose granules are impregnated with the aqueous or aqueous-alcoholic solutions of the activated-potentiated form of the antibodies to the CD4 receptor in the ratio of 1 kg of antibody solution to 5 or 10 kg of lactose (1: 5 to 1:10). To perform impregnation, lactose granules are exposed to irrigation by saturation in the fluidized bulging bed in a boiling bed plant (eg, "Huttlin Pilotlab" by Huttlin GmbH) with subsequent drying by means of heated air flow to a temperature below 40 ° C. The estimated amount of the dried granules (10 to 34 parts by weight) saturated with the activated-enhanced form of the antibodies is placed in the mixer, and mixed with 25 to 45 parts by weight of pure "unsaturated" lactose (which is it uses for the purposes of cost reduction as well as simplification and acceleration of the technological process without diminishing the efficiency of the treatment), together with 0.1 to 1 parts by weight of magnesium stearate, and 3 to 10 parts by weight of microcrystalline cellulose. The mass of the tablet obtained is mixed uniformly, and formed into tablets by means of direct dry pressing (for example, in a Korsch-XL 400 tablet press) to form 150 to 500 mg of round pills, preferably, 300 mg After tablet formation, 300 mg of pills are obtained which are saturated with the aqueous-alcoholic solution (3.0-6.0 mg / plldora) of the activated-potentiated form of the antibodies for the CD4 receptor in the form of a mixture of C12, C30, and C50 centesimal homeopathic dilutions or a mixture of C12, C30 and C200 centesimal homeopathic dilutions.
Preferably, for the purpose of treatment, the combination of the invention is administered from once a day to four times a day, preferably twice a day, each administration including one or two unit dosage combination forms.
The technological result sought by the claimed invention is the increased reliability and reproducibility of the methods for identifying drugs prepared according to homeopathic techniques, that is, drugs that do not contain the molecular form in any practically detectable concentration. In addition, the claimed invention seeks the increased reliability and reproducibility of the methods for determining the pharmacological modifying potency associated with a
5
10
fifteen
twenty
25
30
35
medication, that is, an activated-potentiated form. These methods are performed in vitro, that is, outside the body.
The methods for achieving the technological result of the present invention ultimately seek to determine the degree of modifying power associated with the activated-enhanced form that was acquired during the activation process. The processing of the starting substance containing the molecular form to achieve a medicine prepared by means of homeopathic techniques, that is, the activated-potentiated form, comprises multiple consecutive dilutions with a carrier, thereby decreasing the concentration of the substance of start.
In the context of medicinal bipathic preparations, the potency of the activated-enhanced form is manifested in its ability to alter or affect the physical, chemical and / or biological properties of the therapeutic dose. That is, the claimed invention involves determining the alterations in the physical parameters of the therapeutic dose using the analytical methods after the addition of the activated-potentiated form thereof. Said analytical methods will allow the determination of the presence or absence of the activated-potentiated form in the therapeutic dose. The analytical methods measure one or more physical parameters of the therapeutic dose before and after mixing with the activated-potentiated form. The degree of potency of the therapeutic dose before and after mixing with the activated-potentiated form can also be measured using the analytical methods. Alterations of a characteristic parameter can be provided in relative units.
The measurement of a characteristic parameter can be affected by the presence of the molecular form at detectable levels in the activated-enhanced form. If the molecules of the molecular form are present at detectable levels in the activated-potentiated form, then said molecules need to be removed from the activated-potentiated form before mixing the activated-potentiated form and the therapeutic dose. The absence of the molecular form in a sample is, for the purposes of the present subject matter, synonymous with the inability to detect said molecular form. A means for removing / rendering a molecular form in an activated-potentiated form undetectable is through the additional dilution, for example, centesimal homeopathic dilution. Another means is through a molecular sieve. A molecular sieve is a material with very few holes of exact and uniform size. These holes are small enough to block large molecules while allowing
13
5
10
fifteen
twenty
25
30
35
Let small molecules pass. Examples of molecular sieves include activated carbon and silica gel. Similar to a molecular sieve, any procedure and / or apparatus that has a tendency to stop or even decelerate the molecular form while allowing the carrier to proceed can be used to remove or make the molecular form undetectable. Thus, a process similar to high pressure liquid chromatography ("HPLC") can be used in which the immobile phase of the HPLC apparatus stops or slows down the progress of the molecular form while the mobile phase, comprising the activated form -powered, proceeds through the device relatively unimpeded. Depending on the parameters such as the affinity of the molecular form for the solid phase, the molecular form will be completely absent from the result of the HPLC apparatus for at least a certain known period of time.
Additionally, if molecules of the starting substance are present in the modified solvent, they can be removed using well accepted methods. In particular, the molecules of a protein taken as the starting substance can be removed, for example, by heating the modified solvent to achieve denaturation of the protein followed by filtration. Alternatively, a desalination method can be used where the protein is precipitated by means of high concentrations of neutral salts of alkaline and alkali earth metals followed by filtration. Other possible methods include electrodialysis; deionization using ion exchange resins; Inverse osmosis; and ultrafiltration (molecular filtration) with or without preliminary filtration through larger pores. As additional examples found in the art, refer to, BM Steward, The production of high-purity water in the clinical laboratory, Laboratory Medicine, volume 31 (11), pp. 605-611 (2000); J. Grimm, D. Bessarabov, R. Sanderson, Review of electro-assisted method for water purification, Desalination, volume 115 (3), pp. 285-294 (1998); IA Koznacheev, et al., Water purification of organic infusions in a reverse flow filtration combustion reactor, International Journal of Heat and Mass Transfer, Volume 54, pp. 932-937 (1998); Labconco Corporation, A Guide to Laboratory Water Purification, An Industry Service Publication. http://bioresearchonline.com/doc.mvc/A- Guide-to-Labo while ry-Wate rPurification.
The claimed method can be carried out using different methods of quantitative and qualitative determination, thus ensuring high sensitivity and reproducibility during the test of the presence and potency of an activated-enhanced form. Quantitative and qualitative methods include mass spectrometry such as chromatography and mass spectrometry, gas-liquid chromatography
14
5
10
fifteen
twenty
25
30
35
("GLC") and high performance illiquid chromatography ("HPLC"); NMR spectroscopy, immunoenzyme assay ("IEA").
Chromatography is based on the partition of the components of a mixture caused by the difference in its homogeneous distribution between two inmiscibies phases. One phase in chromatography is immobile (sorbent) while another is mobile (eluent). The high pressure (up to 400 bar) and colloidal solvent suspension (generally 3-5 pm; currently up to 1.8 pm) are hallmarks of HPLC. The qualitative determination using HPLC analysis is based on the evaluation of the retention time of the chromatography peak. The quantitative determination is based on the evaluation of the peak area.
Nuclear magnetic resonance spectroscopy (“NMR spectroscopy”) is a research technique that takes advantage of the magnetic properties of certain atomic nuclei. NMR determines the physical and chemical properties of the atoms or molecules in which they are contained. It is based on the phenomenon of nuclear magnetic resonance and can provide detailed information about the structure, dynamics, reaction state, and chemical environment of the molecules. The intramolecular magnetic field around an atom in a molecule changes the resonance frequency, thus giving access to the details of the electronic structure of a molecule. The software allows the analysis of the intensity of the signal of the peaks, which under conditions of optimal relaxation, correlate with the number of protons of that type. The signal intensity analysis is performed by integration - the mathematical process that calculates the area under a curve, its size is dependent on its area.
An immunoenzyme assay ("IEA") is a biochemical test that measures the presence or
concentration of a macromolecule in a solution through the use of an antibody or
immunoglobulin The macromolecule detected by means of the immunoassay is often
referred to as an "analyte." Ideally, the antibody will bind with the analyte and only at
analyte Once bound to the analyte, the antibody emits a signal indicative of the presence of
A single analyte molecule. This signal could be the immediate spontaneous release of
a photon of light after the binding or release of a photon of light by the bound antibodies
to the analyte after the incidence of a certain "probing" signal. Similarly, the
antibodies bound to the analyte may react differently than antibodies not
linked to a final stage of IEA allowing, for example, the removal of antibodies
unbound and the assessment of the number of remaining bound antibodies. In addition, the
antibodies may be attached to a piezoelectric crystal that undergoes deformation
fifteen
5
10
fifteen
twenty
25
30
35
Elastic when an electric current is applied to it. An alternating electric current (AC) produces a standing wave in the crystal of a characteristic frequency. The frequency is highly dependent on the elastic properties of the crystal, whose properties are affected by what is attached to the crystal. The binding of an objective analyte to an antibody will produce a change in the resonance frequency, which produces a binding signal. Biological methods and other methods are applicable for the realization of the claimed method. See, for example, Zolotov, Yu. A. (editor), Basics of analytical chemistry (in 2 volumes), Textbook for universities, 3rd edition (2004); Vasilyev, V.P., Analytical chemistry, (1989); Otto, M., Up-to-date methods of analytical chemistry, (2003).
Using a combination of analytical methods to detect the molecules of the starting substance in said activated-potentiated carrier and the measurement by analytical methods of at least one characteristic parameter of the starting substance before and after its interaction with said activated carrier- enhanced, we demonstrate (substantiate) that: first, the modifying activity associated with the carrier should not be attributed by the presence of the molecules of the starting substance and that the physical, chemical and / or biological properties of said carrier differ from the properties physical, chemical and / or biological of the starting substance, secondly, the activated-enhanced carrier is obtained by using the starting substance, where the activated-enhanced form is ensured by the same procedure used during the treatment technology of the starting substance and that is represented by multiple reductions in series of the concentration on of the last one with the use of said carrier. Finally, based on in vitro evidence, authenticity and identity are demonstrated for the drug product prepared using said activated-potentiated carrier. That is, starting with the molecular form in therapeutic concentration, the activated-enhanced form is carried out through multiple consecutive decreases in the concentration of the molecular form using the carrier. In addition, the claimed analytical measurement of at least one characteristic parameter of the therapeutic form before its interaction with the activated-enhanced form and again after said interaction serves to quantify the degree of the modifying power associated with the activated-enhanced form in relative dimensionless units of activity (release activity).
The degree of the modifying power corresponding to an activated-enhanced form is determined on the basis of the quantitative alterations of a characteristic parameter
expressed in units of relative activity (liberation activity), formula (1):
16
5
10
fifteen
twenty
25
30
35
X = C | A-Am | / A (1)
X is the number of activity units (UA);
C is a dimensionless constant of proportionality that is contingent on the analytical methods used to measure the characteristic parameter that reflects the initial physical, chemical and / or biological properties of the starting substance and the characteristic parameter value. In particular, for example C = 10k, where k is an integer of the sequence 1, 2, 3 etc .;
A is the value of a characteristic parameter of the starting substance before its interaction with said activated-enhanced form (technologically treated carrier);
Am is the value of the same characteristic parameter of the starting substance after its interaction with said activated-enhanced form (technologically treated carrier).
The claimed method can be carried out using different quantitative and qualitative determination methodologies, thereby ensuring high sensitivity and reproducibility in ultra-low concentrations of the test substance, such as spectrometry, in particular mass spectrometry, chromatography. Mass spectrometry (gas-liquid chromatograph (GLC)) and high performance liquid chromatograph (HPLC) based on the separation of the components of a mixture caused by the difference in its homogeneous distribution between two immiscible phases. One phase in the chromatograph is immobilized (sorbent) and the other is mobile (eluent). The high pressure (up to 400 bars) and the sorbent slurry (in general 3 to 5 pm; here up to 1.8 pm) are hallmarks of HPLC. The qualitative determination using HPLC analysis is based on the evaluation of the retention time of the chromatographic peak. The quantitative determination is based on the evaluation of the area of the peak.
Another technique that is used in the realization of the claimed method is nuclear magnetic resonance spectroscopy (NMR spectroscopy) that takes advantage of the magnetic properties of certain atomic nuclei. NMR determines the physical and chemical properties of the atoms or molecules in which they are contained. It relies on the phenomenon of resonance absorption and the emission of electromagnetic energy by substances with zero-link nuclei when placed in a
5
10
fifteen
twenty
25
30
35
external magnetic field at a frequency v (called the NMR frequency) that is induced by the reorientation of the magnetic nuclear moments, where a so-called chemical shift is the characteristic parameter. In addition, the mentioned techniques include an enzymatic immunoassay (IEA), the use of a piezoelectric immunosensor whose analytical signal is represented by a difference in the resonance frequency of the piezoelectric resonator (A f) resulting from increases or decreases in the weight of the layer covered by the recipient due to the formation and destruction of the immune complex on its surface. The biological methods as! like other methods, they can also be applied for the realization of the claimed method (for example, see Zolotov, Yu. A. (editor), Basics of analytical chemistry (2 volumes), Textbook for universities, 3rd edition, revised and complemented: Vysshaya shkola Publisher (2004); Vasilyev, VP, Analytical chemistry, (1989); Otto, M., Up-to-date methods of analytical chemistry, (2003). Additionally, if the molecules of the starting substance are present in the solvent modified, they can be removed using well-accepted methods.In particular, the molecules of a protein taken as the starting substance can be removed, for example, by heating the modified solvent to achieve denaturation of the protein followed by filtration. alternatively, a desalination method can be used where the protein is precipitated by means of high concentrations of neutral salts of alkaline and alkali earth metals followed by filtration. Possible methods include electrodialysis; deionization using ion exchange resins; Inverse osmosis; and ultrafiltration (molecular filtration) with or without preliminary filtration through larger pores. As additional examples found in the art, refer to, BM Steward, The production of high-purity water in the clinical laboratory, Laboratory Medicine, 2000, volume 31 (11), pp. 605-611; J. Grimm, D. Bessarabov, R. Sanderson, Review of electro-assisted methods for water purification, Desalination, 1998, volume 115 (3), pp. 285-294; IA Koznacheev, et al., Water purification of organic inclusions in a reverse flow filtration combustion reactor, International Journal of Heat and Mass Transfer, 1998, Volume 54, pp. 932-937; Labconco Corporation, A Guide to Laboratory Water Purification, An Industry Service Publication. http://bioresearchonline.com/doc.mvc/A-Guide-to- Laboratory-WaterPurification. (BCTaBHTb npaBH ^ bHyro ccbMKy).
By using a combination of analytical methods to detect the molecules of the starting substance in said activated-potentiated carrier and the measurement by analytical methods of at least one characteristic parameter of the starting substance before and after its interaction with said activated carrier -powering, we show
(we substantiate) that: first, the modifying activity associated with the carrier must not be
18
5
10
fifteen
twenty
25
30
35
attributed by the presence of the molecules of the starting substance and that the physicochemical and / or biological properties of said carrier differ from the physicochemical and / or biological properties of the starting substance, secondly, the activated-enhanced carrier is obtained through the use of the starting substance, where the activated-enhanced form is achieved through the same procedure used during the technological treatment of the starting substance, that is, multiple serial reductions of the concentration of the latter with the use of said carrier. Finally, based on in vitro evidence, authenticity and identity are demonstrated for the drug product prepared using said activated-potentiated carrier.
In addition, the claimed analytical measurement of at least one characteristic parameter of the starting substance before and after its interaction with the activated-enhanced carrier serves to quantify the degree of the modifying power associated with the carrier in relative dimensionless units of activity ( release activity)
To determine the degree of modifying power associated with the carrier, the following consecutive procedures are carried out:
to. preparation of the carrier with enhanced modifying activity in the course of technological processing (treatment) of the starting substance by multiple stages of serial reduction of the concentration using said carrier, wherein the latter does not contain the molecular form of said starting substance.
b. performance of the specificity tests of the substance present in the solution of step a.), which includes
i. treatment of the molecular form of the starting substance with the carrier indicated in step a.)
ii. preferably, treatment of the molecular form of a different substance and / or solvent with the carrier indicated in step a.)
analytical measurement of at least one physical and / or biological parameter characteristic of said molecular form of the starting substance (A) and said combination under paragraph b.) (Am), wherein said carrier specifically modifies the effect-ability to modifying the physicochemical and / or biological properties of the starting substance is considered specific to the substance if the change in said characteristic parameter with the realization of paragraph b.) i.) is statistically significant (and not statistically significant with the realization of the paragraph b.) ii.))
5
10
fifteen
twenty
25
30
35
C. determination of the modifying power associated with the carrier in units of
relative activity using equation (1):
X = C | A-Am | / A (1)
X, C, A and Am are as previously defined, where C is preferably equal to 100 or 1000.
Examples
The present invention is now illustrated by means of the following Examples, which do not limit the scope of the present invention in any way.
Abbreviations generally used in the Examples:
Ab - antibodies
ELISA or IEA - solid phase enzyme immunoassay
OD - optical density
IFN-gamma - interferon gamma
HPLC - high performance liquid chromatograph
AC - activated-enhanced form
PBS-phosphate regulated saline solution
APBS-phosphate-regulated saline solution activated according to the homeopathic IgG - immunoglobulin G technique, including antibodies to interferon gamma ("IFN-gamma") water A - water activated according to the homeopathic UV / Vis technique - Ultraviolet until visible spectroscopy
Example 1
The purpose of Example 1 is to determine the degree of modifying potency of the activated-enhanced form of rabbit Ab for human IFN-gamma. Starting with a rabbit Ab mother stock solution for human IFN-gamma, an activated-potentiated form of rabbit Ab for human IFN-gamma was prepared by multiple consecutive dilutions decreasing the concentration of the starting substance accompanied by multiple intermediate agitations. The diluent, that is, the carrier, was a water-alcohol solution. The molecular form was diluted in 10012, 10030 and 10050 parts of the carrier, that is, the homeopathic dilutions C12, C30, C50. To determine the alterations of the physical, chemical and / or biological properties of the starting substance, that is, the Ab
5
10
fifteen
twenty
25
30
35
Rabbit for human IFN-gamma, HPLC was applied while the volume of the substance was used as the characteristic parameter.
The quantitative determination of the substance was based on the evaluation of the peak area value using HPLC. The IgG + AC mixture was selected as the test sample. As control samples the following mixtures were used: IgG + water A, IgG + water and IgG + APBS.
Test samples were prepared by mixing IgG (50 mg / ml) and AC (or water A or APBS or water) in a 1: 2 ratio (v / v). The resulting mixtures were filtered using cellulose acetate membrane filters, pore size - 0.45 pm.
The analysis was carried out with separation by HPLC in gradient mode. An anion exchange column was applied as a stationary phase; The 2 phase mixture (phase 1 - acetonitrile, phase 2 - potassium hydrogen phosphate solution and potassium chloride solution) were used as the mobile phase. A UV-Vis detector was applied for the purpose of detection; wavelength - 280 nm.
Calibration and zeroing of the baseline of the UV-Vis detector were carried out before and after each analysis.
The prepared mixtures were transferred to bottles and introduced into the chromatography system using the automatic sample processor. The analysis time for each of the test samples was approximately 23 minutes.
After the completion of the analysis, the chromatographic column equilibration was run at a constant flow rate under the conditions of the gradient of the mobile phase similar to those at the beginning of the analysis.
The signal emitted by the test samples was recorded in the form of peak chromatogram, which is assumed to correspond to light and heavy IgG chains. The area of the first maximum of the spectrophotometric peaks was calculated (Max -1 corresponds to the immunoglobulin heavy chains) and the second maximum (Max -2 corresponds to the immunoglobulin light chains). The results of this analysis are presented in Table 1.
Table 1. Areas of maximum chromatographic peak
twenty-one
5
10
fifteen
twenty
25
 Test sample  Maximum peak chromatographic area Substance modifying power in AU at C = 100
 Max-1  Max-2 Max-1 Max-2
 IgG + AC  17207.9 ± 434.7 45860.6 ± 9427.3
 IgG + water  30270.2 ± 980.6 5577.4 ± 467.5 43.2 722.3
 IgG + water A  28704.0 ± 4265.3 5626 ± 686.6 40.1 715.2
 IgG + APBS  25888.7 ± 1514.1 7135.7 ± 746.0 33.5 542.7
The degree of modifying power is calculated by applying equation (1):
(X = C | A-A „| / A)
where C = 100. Equation (1) applies to the IgG + AC sample and the IgG + water sample, resulting in:
(Max-1) A = 30270.2; AM = 17207.9; X = 43.2 AU;
(Max-2) A = 5577.4; Am = 45860.6; X = 722.3AU
Experiments showed that AC for IFN-gamma decreases the area of the first peak of IgG peak (Max-1 corresponds to heavy chains of immunoglobulin) and increases the area of second maximum of peak IgG (Max-2 corresponds to light chains of immunoglobulin) compared to controls.
The results of Example 1 support the following conclusions:
1. Due to the technique used for the preparation of homeopathic dilutions C12, C30, C50, an activated-potentiated form comprising a mixture of these three homeopathic dilutions a priori does not contain molecules of the starting substance;
2. Alterations of the physical and chemical properties of the starting substance, Rabbit Ab for human IFN-gamma, treated by the activated-potentiated form present reliable evidence that said activated-potentiated form is prepared on the basis of the substance boot-IFN-gamma;
3. The alterations of the physical and chemical properties of the starting substance, Rabbit Ab for human IFN-gamma, treated by the activated-enhanced form significantly validates the degree of modifying power associated with the form
5
10
fifteen
twenty
25
30
35
activated-enhanced and provides the opportunity to express said modifying power revealed by using the HPLC technique in dimensionless activity units according to equation (1) (Table 1).
Example 2
The purpose of Example 2 is to determine the degree of modifying power of the activated-potentiated form of rabbit Ab for human IFN-gamma. Starting with a rabbit Ab mother stock solution for human IFN-gamma, an activated-potentiated form of rabbit Ab for human IFN-gamma was prepared by multiple consecutive dilutions decreasing the concentration of the starting substance accompanied by multiple intermediate agitations. The diluent, that is, the carrier, was a water-alcohol solution. The molecular form was diluted in 10012, 10030 and 10050 parts of the carrier, that is, the homeopathic dilutions C12, C30, C50. To determine the alterations of the physical, chemical and / or biological properties of the starting substance, that is, rabbit Ab for human IFN-gamma, HPLC was applied while the volume of the substance was used as the characteristic parameter.
The quantitative determination of the substance was based on the evaluation of the peak area value using HPLC. The Ab mixture for IFN-gamma + AC was selected as the test sample. As control samples the following mixtures were used: Ab for IFN-gamma + water A, Ab for IFN-gamma + water and Ab for IFN-gamma + APBS.
Test samples were prepared by mixing Ab for IFN-gamma and AC (or water A or APBS or water) in the 1: 1 ratio (v / v). The resulting mixtures were subjected to vortexing for 15 seconds, incubated at room temperature for 18 hours and then AC, water A, APBS or water was added.
The analysis was carried out with separation by HPLC in gradient mode. A reverse phase octadecylsilane column was applied as a stationary phase; The 2-phase mixture (phase 1 - acetonitrile supplemented with acetic acid and trifluoroacetic acid, phase 2 - deionized water with metallic acid and trifluoroacetic acid) was used as the mobile phase. A UV-Vis detector was applied for the purpose of detection; wavelength - 280 nm.
Calibration and zeroing of the baseline of the UV-Vis detector were carried out before and after each analysis.
5
10
fifteen
twenty
25
The prepared mixtures were transferred to bottles and introduced into the chromatography system using the automatic sample processor. The analysis time for each of the test samples was approximately 15 minutes.
After the completion of the analysis, the chromatographic column equilibration was run at a constant flow rate under the conditions of the gradient of the mobile phase similar to those at the beginning of the analysis.
The signal emitted by the test samples was recorded in the form of peak chromatogram of the corresponding protein. The spectrophotometric peak area was calculated. The results of this analysis are presented in Table 2.
Table 2. Area of maximum chromatographic peak
 Test sample  Peak chromatographic area Substance modifying power at AU at C = 100
 Ab for INF-gamma + AC form of Ab for IFN-gamma  113.1 ± 3.6
 Ab for INF-gamma + water A  123.2 ± 3.6 8.2
 Ab for INFgamma + water  128.3 ± 0.3 11.8
It was shown that the activated-enhanced form of Ab for IFN-gamma reduces the peak area of Ab for IFN-gamma compared to controls.
The results of Example 1 support the following conclusions:
1. Due to the technique used for the preparation of homeopathic dilutions C12, C30, C50, an activated-potentiated form comprising a mixture of these three homeopathic dilutions a priori does not contain molecules of the starting substance;
2. Alterations of the physical and chemical properties of the starting substance, Rabbit Ab for human IFN-gamma, treated by the activated-enhanced form significantly validates that said activated-enhanced form is prepared on the basis of the substance Boot-Ab for interferon gamma (anti-IFN-gamma);
3. Alterations of the physical and chemical properties of the starting substance, Rabbit Ab for human IFN-gamma, treated by the activated-enhanced form significantly validates the degree of modifying power associated with the activated-enhanced form and provides the opportunity to express such modifying power
5
10
fifteen
twenty
25
30
35
revealed by using the HPLC technique in dimensionless activity units according to equation (1) (Table 2).
Example 3
The purpose of Example 3 is to determine the degree of modifying power of the activated-potentiated form of diclofenac sodium. Starting with a stock solution of diclofenac sodium, an activated-potentiated form of diclofenac sodium was prepared by multiple consecutive dilutions decreasing the concentration of the starting substance accompanied by multiple intermediate agitations. The diluent, that is, the carrier, was a water-alcohol solution. The molecular form was diluted in 10012, 10030 and 100200 parts of the carrier, that is, the centesimal homeopathic dilutions C12, C30, C200. To determine the alterations of the physical, chemical and / or biological properties of the starting substance, that is, diclofenac sodium, HPLC was applied while the volume of the substance was used as the characteristic parameter.
The quantitative determination of the substance was based on the evaluation of the peak area value using HPLC. The diclofenac + lactose mixture, saturated with AC, was selected as the test sample. As control samples the following mixtures were used: diclofenac + lactose, saturated with APBS, and diclofenac + unsaturated lactose.
Test samples were presented in the form of diclofenac sodium powder, unsaturated lactose and lactose saturated with AC (APBS). The powders were dissolved in distilled water, the ratio of heavy amount of diclofenac and heavy amount of lactose was 1: 3; the volume of water used for the solution was identical. The prepared solutions were mixed with diclofenac sodium solution in the 1: 3 ratio (v / v). The solutions were mixed by vertical shaking of the jars for 15 seconds. A double distilled was used to dilute the solution mixture in order to reach the final concentration of 0.3 pg / ml. The solutions were subjected to manual agitation for 15 seconds by vertical shaking of the flasks. The resulting mixtures were incubated in a dark place at room temperature for 18 hours.
The analysis was carried out with separation by HPLC in gradient mode. The column packed with silica gel and modified with octadecyl was applied as stationary phase; the mixture of 2 phases (phase 1 - distilled water with formic acid and trifluoroacetic acid, phase 2 - acetonitrile with formic acid and trifluoroacetic acid) were used as the mobile phase. A UV-Vis detector was applied for the purpose of detection; wavelength - 276 nm.
25
5
10
fifteen
twenty
25
Calibration and zeroing of the baseline of the UV-Vis detector were carried out before each analysis.
The prepared mixtures were transferred to bottles and introduced into the chromatography system using the automatic sample processor. The analysis time for each of the test samples was approximately 15 minutes.
After the completion of the analysis, the chromatographic column equilibration was run at a constant flow rate under the conditions of the gradient of the mobile phase similar to those at the beginning of the analysis.
The signal emitted by the test samples was recorded in the form of peak chromatogram corresponding to diclofenac. The spectrophotometric peak area was calculated. The results of this analysis are presented in Table 3 (the detection was carried out at 276 nm).
Table 3. The area of maximum chromatographic peak
 Test sample  Peak chromatographic area Substance modifying power at AU at C = 100
 Diclofenac + lactose saturated with AC  66039.3 ± 549.1
 Diclofenac + lactose saturated with APBS  42652.0 ± 484.2 54.8
 Diclofenac + unsaturated lactose  32004.3 ± 1113.7 106.3
It was shown that the peak area of diclofenac mixed with AC exceeds the peak area of diclofenac mixed with controls, that is, unsaturated lactose and lactose saturated with APBS.
The results of Example 3 support the following conclusions:
1. Due to the technique used for the preparation of homeopathic dilutions C12, C30, C50, an activated-potentiated form comprising a mixture of these three homeopathic dilutions a priori does not contain molecules of the starting substance;
5
10
fifteen
twenty
25
30
35
2. Alterations of the physical and chemical properties of the starting substance, diclofenac, treated by the activated-enhanced form of diclofenac, validates significantly that said activated-enhanced form is prepared on the basis of the starting substance-diclofenac ;
3. Alterations of the physical and chemical properties of the starting substance, diclofenac, treated by means of the activated-enhanced form of diclofenac significantly validates the degree of modifying power associated with the activated-enhanced form and provides the opportunity to express such Modifying power revealed by using the HPLC technique in dimensionless activity units according to equation (1) (Table 3).
Example 4
The purpose of Example 4 is to determine the degree of modifying power of the activated-enhanced form of rabbit Ab for human IFN-gamma. Starting with a rabbit Ab mother stock solution for human IFN-gamma, an activated-enhanced form of rabbit Ab for human IFN-gamma was prepared by multiple consecutive dilutions decreasing the concentration of the starting substance accompanied by multiple intermediate agitations. The diluent, that is, the carrier, was a water-alcohol solution. The molecular form was diluted in 10012, 10030 and 10050 parts of the carrier, that is, the homeopathic dilutions C12, C30, C50. To determine the alterations of the physical, chemical and / or biological properties of the starting substance, that is, rabbit Ab for human IFN-gamma, ELISA was applied while the alteration in the number of antigen-antibody complexes was used. as the characteristic parameter.
Before carrying out the analysis, Ab for IFN-gamma and AC (or APBS used as a placebo) were pre-incubated for 24 hours at 4 ° C; during Ab incubation for IFN-gamma, it was linked to the IFN-gamma contained in the solution. After incubation, each sample was exposed to an ELISA plate that has a solid phase antigen surface. The Ab for IFN-gamma previously bound to the IFN-gamma was adsorbed onto the solid phase of the ELISA plate. The Ab for IFN-gamma that remains unbound to IFN-gamma after incubation was left in the solution.
The resulting samples were tested according to the ELISA procedures. The
amount of antigen-antibody complexes formed adsorbed on the solid phase was
determined by measuring the optical density of the solutions in dish wells taking in
Consideration of the reaction of extinction of the chromogen solution, whose color changes
27
5
10
fifteen
twenty
25
30
35
on the background of the enzyme-induced decomposition of the substrate. To determine the extinction of the solution, the spectrophotometric technique was applied at a wavelength of 490 nm in a single wave mode. The more antigen-antibody complexes formed on a plate, the less Ab for IFN-gamma was linked to the IFN-gamma in the solution.
The average OD of the samples for 2 similar experiments incubated with CA was 0.603 ± 0.075 (when AC or placebo were immediately mixed with the antigen and with Ab for IFN-gamma and were incubated for 24 hours) or 0.251 ± 0.027 (when AC or placebo were mixed with Ab for IFN-gamma while after incubation for 40 minutes antigen was added and incubation was carried out for 24 hours) while for IFN-gamma incubated with APBS the optical density values were 0.812 ± 0.084 and
0. 391.0.023 respectively.
Experiments have shown that aqueous solutions of AC decreased the number of antigen-antibody complexes in the solution compared to the control, which validates the identity of the drug containing rabbit antibodies to human interferon-gamma (Ab for IFNy ).
The results of Example 4 support the following conclusions:
1. Due to the technique used for the preparation of homeopathic dilutions C12, C30, C50, an activated-potentiated form comprising a mixture of these three homeopathic dilutions a priori does not contain molecules of the starting substance;
2. Alterations of the physical and chemical properties of the starting substance, Rabbit Ab for human IFN-gamma, treated by the activated-enhanced form significantly validates that said activated-enhanced form is prepared on the basis of the substance IFN-gamma starter;
3. Alterations of the physical and chemical properties of the starting substance, Rabbit Ab for human IFN-gamma, treated by the activated-enhanced form significantly validates the degree of modifying power associated with the activated-enhanced form and provides the opportunity to express said modifying power revealed by using the HPLC technique in dimensionless activity units according to equation (1) (Table 2). The degree of modifying activity calculated using equation (1) (compared to placebo) was 25.7-35.8 AU.
5
10
fifteen
twenty
25
30
35
Example 5
The purpose of Example 5 is to determine the degree of modifying potency of the activated-enhanced form of rabbit Ab for human IFN-gamma. Starting with a rabbit Ab mother stock solution for human IFN-gamma, an activated-potentiated form of rabbit Ab for human IFN-gamma was prepared by multiple consecutive dilutions decreasing the concentration of the starting substance accompanied by multiple intermediate agitations. The diluent, that is, the carrier, was a water-alcohol solution. The molecular form was diluted in 10012, 10030 and 10050 parts of the carrier, that is, the homeopathic dilutions C12, C30, C50. To determine the alterations of the physical, chemical and / or biological properties of the starting substance, that is, rabbit Ab for human IFN-gamma, the ability of the adsorbed antibodies on a piezoelectric immunosensor surface to bond with the antigen treated by the activated-potentiated form.
Specific abbreviations for Example 5:
Af-alterations of the oscillation frequency of the APTS piezoelectric immunosensor - y-aminopropyltriethoxysilane Sr - standard deviation
An analytical signal of a piezoelectric immunosensor comprises a change in the frequency of oscillation (Af) of a quartz crystal resonator depending on the increase or decrease in the mass of the bioreceptor. Said change in mass may arise from the formation or destruction of an immune complex on the sensor surface. During the given study the effect of the composition of the analyzed samples on the analytical signal of the sensor was evaluated. A mixture of IFN-gamma and the activated-potentiated form ("AC") of the IFN-gamma was selected as the test sample. A mixture of IFN-gamma and APBS was used as a control sample. The samples were tested in The form of aqueous solutions.
To create the immunosensor, a bio-recognition receptor layer based on APTS was formed on a piezoelectric element. Using the micro syringe surface of the gold sensor electrode (diameter 8 mm) which was accordingly coated with 0.8 pl of APTS (which was dried in a desiccator for 20 minutes at 80 ° C), 5 pL of glutaraldehldo ( 2.5% solute in distilled water) and then 5 pl of antibody solution for IFN-gamma (9.6 ng / ml). For each measurement a new biorecognition receptor layer was formed.
5
10
fifteen
twenty
25
30
Preliminary sample preparation included mixing 50 µl of IFN-gamma (30 mg / ml) with 50 µl of the test sample. The sample was then heated for 45 minutes at 37 ° C and mixed for 10 minutes by centrifugation (1000 rpm). The surface of the immobilized Ab sensor for IFN-gamma was coated with 2.5 pl of the resulting solution, maintained for minutes, washed with distilled water, dried to acquire constant weight and the measurement of the static signal of the sensor was carried out. . Alterations of the antigen-antibody binding were evaluated from the alteration in the mass of the interferon molecule.
Piezoelectric resonators made of an AT cut quartz crystal with 8 mm gold electrode (ZAO ETNA, Moscow) were used as sensors. To record the analytical signal, a personal computer and a DiScope transducer (NPP Bafika, Moscow) were applied.
The results of the experiment are presented in Table 4.
Table 4. Effect of the test sample composition on the sensor analytical signal
 Sample Composition  Af (M ± SD) Substance modifying power at AU at C = 100
 IFN-gamma + AC  89 ± 4
 IFN-gamma + APBS  123 ± 5 2764.2
Experiments have shown that the addition of the activated-enhanced form to the therapeutic form of IFN-gamma affects the frequency of the piezoelectric resonator inducing its reduction compared to the controls.
The results of Example 5 support the following conclusions:
1. Due to the technique used for the preparation of homeopathic dilutions C12, C30, C50, an activated-potentiated form comprising a mixture of these three homeopathic dilutions a priori does not contain molecules of the starting substance;
2. The alterations of the physical and chemical properties of the starting substance, IFN-gamma, treated by the activated-enhanced form validates significantly that said activated-enhanced form is prepared on the basis of the starting substance-Ab for interferon gamma (anti-IFN-gamma);
3. Alterations of the physical and chemical properties of the starting substance,
Rabbit ab for human IFN-gamma, treated by the activated-enhanced form
30
5
10
fifteen
twenty
25
30
35
it significantly validates the degree of modifying power associated with the activated-enhanced form and provides the opportunity to express said modified modifying power by utilizing a piezoelectric sensor in dimensionless activity units according to equation (1) (Table 4) . The degree of modifying activity calculated using equation (1) (compared to placebo) was 2764.2 AU.
Example 6
Analysis of alterations in neutralizing activity of antibodies to IFN-gamma treated by the release of active antibodies to IFN-gamma; The method applied is the measurement of neutralizing activity.
The purpose of Example 6 is to determine the degree of modifying power of the activated-enhanced form of rabbit Ab for human IFN-gamma. Starting with a rabbit Ab mother stock solution for human IFN-gamma, an activated-potentiated form of rabbit Ab for human IFN-gamma was prepared by multiple consecutive dilutions decreasing the concentration of the starting substance accompanied by multiple intermediate agitations. The diluent, that is, the carrier, was a water-alcohol solution. The molecular form was diluted in 10012, 10030 and 10050 parts of the carrier, that is, the homeopathic dilutions C12, C30, C50. To determine the alterations of the physical, chemical and / or biological properties of the starting substance, that is, rabbit Ab for human IFN-gamma, the alteration of the neutralizing activity of Ab for IFN-gamma treated by means of activated-enhanced form of Ab for IFN-gamma while the alteration in the number of surviving cells after viral infection was used as the characteristic parameter.
Specific abbreviations for Example 6:
R (X) - RPM1-1640, culture medium containing X% - bovine fetal serum NA - CPE neutralizing activity - cytopathic effect
The neutralizing activity, measured as NA / ml, of drugs containing antibodies is based on the inhibition of IFN-gamma binding with its receptor expressed in the cell membrane.
5
10
fifteen
twenty
25
30
35
Neutralizing activity of polyclonal rabbit Ab samples for IFN-gamma in culture medium R (1)] in the presence of the activated-potentiated form ("AC") or a control sample (distilled water).
Cultivated human embryonic pulmonary fibroblast HEp-2 cells were trypsinized, suspended in 10 ml R (10) and placed on a plate at a concentration of 2.3 x 105 cells / well (100 pl / well). The cells were incubated 24 hours at 37 ° C in a humidified incubator with 7% CO2. The IFN-gamma was subjected to dilution in stages in R (1), from 500 ng / ml to 3.9 ng / ml and inserted into the wells. Polyclonal rabbit antibodies for IFN-gamma (2 consecutive dilutions in (1) starting from the milesimal dilution) and mixed with the IFN-gamma in fixed concentration (250 ng / ml) and AC (10% (v / v) in R (1)) or in distilled water (10% (v / v in R (1)). The dishes were incubated 1 hour at 37 ° C.
After incubation, the wells were emptied and the vesicular stomatitis virus in R (1) was added in the amount of 100 pl / well. After the cells were incubated for 20-24 hours at 37 ° C until the CPE in the control line wells exceeded 90%.
After removal of the cultured medium, the remaining cells were washed with PBS (200 pl / well) and treated with methylrosaniline chloride in formalin (50 pl / well) for 15 minutes at room temperature. 100% monolayer staining was observed when all cells were alive; if the cells were dead (CPE) the monolayer staining was not observed.
The dish was washed with water. Wells with dilutions demonstrating approximately 50% CPE were visually identified and then tested using metrla spectrophot.
The evaluation of the effect is based on the number of surviving cells (ratio of surviving cells to the total number of cells). The reduction of the neutralizing activity of Ab for IFN-gamma was considered to be the criterion of evaluation of the effect of the activated-potentiated form. To calculate the neutralizing activity of the drugs, the following equation was applied: F x A x 10 / C, where F = the reciprocal value of the antibody dilution, A = EU / ml of the standard drug at 50% CPE, and C = antibody concentration (mg / ml).
5
10
fifteen
twenty
25
30
35
The experiment has shown that:
- when human IFN-gamma (500 ng / 1 ml of culture medium) is incubated with human embryonic fibroblast, lung-derived cell-line HEp-2 cells (2.3 x 105 cells / well) infected with the virus vesicular stomatitis (1.6 x 105 PFU / ml), the complete inhibition of the cytopathic effect of the virus was appreciated (100% of infected cells survived);
- when human IFN-gamma (500 ng / 1 ml of culture medium) and rabbit polyclonal Ab for IFN-gamma (0.525 pg / 1 ml of culture medium) are incubated with human embryonic fibroblast, HEp-2 cell lines derived from lung (2.3 x 105 cells / well) infected with vesicular stomatitis virus (1.6 x 105 PFU / ml), 50% inhibition of the cytopathic effect of the virus (50% of cells) was appreciated infected survived);
- when human IFN-gamma (500 ng / 1 ml of culture medium) and rabbit polyclonal Ab for IFN-gamma (0.525 pg / 1 ml of culture medium) are incubated, as! as well as the activated-potentiated form (10% (v / v) of the culture medium) human embryonic fibroblast, HEp-2 cells of lung-derived cell line (2.3 x 105 cells / well) infected with stomatitis virus vesicular (1.6 x 105 PFU / ml), 75% inhibition of the cytopathic effect of the virus was appreciated (75% of infected cells survived);
Apart from that it was revealed that the activated-potentiated form produced the modulation effect on the polyclonal antibodies that modulate the activity.
The results of Example 6 support the following conclusions:
1. Due to the technique used for the preparation of homeopathic dilutions C12, C30, C50, an activated-potentiated form comprising a mixture of these three homeopathic dilutions a priori does not contain molecules of the starting substance;
2. Alterations of the physical and chemical properties of the starting substance, Rabbit Ab for human IFN-gamma, treated by the activated-enhanced form significantly validates that said activated-enhanced form is prepared on the basis of the substance Rabbit Ab starter for human IFN-gamma;
3 Alterations of the physical and chemical properties of the starting substance treated by the aforementioned - said activated-enhanced form significantly validates the degree of modifying power associated with the carrier and provides the opportunity to express said modifying power in units of dimensionless activity according to equation (1), which, based on the measurements of the neutralizing activity, was equal to 50 AU.
5
10
fifteen
twenty
25
30
35
Example 7
The purpose of Example 7 is to determine the degree of modifying power of the activated-enhanced form of rabbit Ab for human IFN-gamma. Starting with a rabbit Ab mother stock solution for human IFN-gamma, an activated-potentiated form of rabbit Ab for human IFN-gamma was prepared by multiple consecutive dilutions decreasing the concentration of the starting substance accompanied by multiple intermediate agitations. The diluent, that is, the carrier, was a water-alcohol solution. The molecular form was diluted in 10012, 10030 and 10050 parts of the carrier, that is, the homeopathic dilutions C12, C30, C50. To determine the alterations of the physical, chemical and / or biological properties of the starting substance, that is, rabbit Ab for human IFN-gamma, by means of the activated-enhanced form of Ab for human IFN-gamma, spectroscopy was used. and NMR while information about the molecular structure of the substance was used as the characteristic parameter.
To determine the conformational alterations of the antibodies for IFN-gamma (Ab for IFN-gamma) treated by the activated-potentiated form ("AC"), NMR spectroscopy was applied Homeopathic dilutions of purified water were used as control.
To prepare the AC or purified water test samples, it was mixed with Ab solution for IFN-gamma in the ratio 2: 1. The final concentration of Ab for IFN-gamma in each sample was 0.8 mg / ml.
A Brucker Advance 700 NMR instrument (operating at the frequency of 700 MHg) was used to carry out the experiment. Test samples were introduced into the device's magnetic field. The excitation of the 1H hydrogen hydrogen isotope was observed. The signal of the test samples was recorded in the form of NMR spectra (signal accumulation for 12 hours), which characterizes the structure and conformational state of Ab for IFN-gamma.
The evaluation of the conformational condition of Ab for IFN-gamma was carried out in the framework of the comparative analysis of the spectra acquired from the sample containing Ab for IFN-gamma + AC or Ab for IFN-gamma + purified water. The comparison was carried out by spectral overlap with the appropriate scaling.
The results of the study showed that the addition of the activated-enhanced form to Ab for IFN-gamma produced alterations in the Ab spectrum for IFN-gamma in the range
3. 4
5
10
fifteen
twenty
25
8-8.5 ppm, 7.6-7.8 ppm, 6-6.6 ppm compared to the Ab spectrum for IFN-gamma + purified water. Figure 1 shows the superposition of the spectra of Ab for IFN-gamma + AC and Ab for IFN-gamma + purified water.
The experiment has shown that the activated-potentiated form affects the conformation of Ab for IFN-gamma in solution.
The results of Example 7 support the following conclusions:
1. Due to the technique used for the preparation of homeopathic dilutions C12, C30, C50, an activated-potentiated form comprising a mixture of these three homeopathic dilutions a priori does not contain molecules of the starting substance;
2. Alterations of the physical and chemical properties of the starting substance, Rabbit Ab for human IFN-gamma, treated by the activated-enhanced form significantly validates that said activated-enhanced form is prepared on the basis of the substance Rabbit Ab starter for human IFN-gamma;
3. The alterations of the physical and chemical properties of the starting substance treated in said activated-enhanced form significantly validates the degree of modifying power associated with the activated-enhanced form.
The description, examples and drawings contained herein represent the presently preferred configuration of the present invention and are, as such, a representation of the subject matter which is widely contemplated by the present invention. The scope of the present invention fully encompasses other configurations that could be made obvious to those skilled in the art, and the scope of the present invention is therefore limited solely and exclusively by the appended claims.

权利要求:
Claims (9)
[1]
5
10
fifteen
twenty
25
30
35
1. A method for determining the activity of the activated-potentiated form of a substance, said method comprises:
provide an activated-potentiated form of a substance,
ensure the absence of the molecular form of the substance in said activated-enhanced form,
provide a molecular form of said substance,
measuring at least one physical, chemical or biological parameter (A) of said molecular form of said substance using a suitable analytical method,
treating said molecular form of said substance with said activated-enhanced form of said substance, and
measuring said at least one physical, chemical or biological (AM) parameter of said treated molecular form of said substance using said analytical method, characterized in that said activity of said activated-enhanced form of said substance is the degree of difference between A and AM .
[2]
2. The method according to Revindication 1, which further comprises expressing said activity of said activated-enhanced form of said substance in relative units (X) in accordance with formula X = C (A-AM) / A, where C it is a dimensionless constant of proportionality that is C = 10k where k is an integer of the sequence 1, 2, 3, etc.
[3]
3. The method according to Revindication 1, further comprising i) treating a molecular form of a different substance with said activated-enhanced form of the first substance, ii) measuring said at least one physical, chemical or biological parameter ( B) of said molecular form of said different substance with said analytical method, iii) measuring said at least one physical, chemical or biological (BM) parameter of said treated molecular form of said different substance using said analytical method to determine the specificity of said method, characterized in that said method is considered specific when said at least one physical, chemical or biological parameter changes in statistically significant mode for A-AM and does not change in statistically significant mode for B-BM.
[4]
4. The method according to Revindication 1, characterized in that said analytical method is a high performance liquid chromatograph.
[5]
5. The method in accordance with Revindication 1, characterized in that said analytical method is immunoenzymatic analysis.
[6]
6. The method in accordance with Revindication 1, characterized in that said analytical method is nuclear magnetic resonance.
36
[7]
7. The method according to Claim 1, characterized in that said step of ensuring the absence of the molecular form of the substance comprises removing the molecular form of said substance.
[8]
8. The method according to Claim 1, characterized in that said substance is an antibody.
The method according to Claim 8, characterized in that said antibody is a polyclonal antibody.
The method according to Claim 1, characterized in that said substance is a small organic molecule.
The method according to Claim 1, characterized in that said form
activated-enhanced is a liquid.
[12]
12. The method according to Claim 1, characterized in that said activated-enhanced form is impregnated on a solid carrier.
fifteen

类似技术:

---

公开号 | 公开日 | 专利标题

---

ES2560897A2|2016-02-23|Method for determining degree of modified potency of bipathic medicament

---

AU2011287292B2|2017-02-02|Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

---

US8987206B2|2015-03-24|Method of treating attention deficit hyperactivity disorder

---

US20120294899A1|2012-11-22|Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV

---

AU2011278039B2|2015-07-23|A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system

---

US20120263725A1|2012-10-18|Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV

---

US20120258146A1|2012-10-11|Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy

---

MX2013001450A|2013-10-25|Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein.

---

US9945798B2|2018-04-17|Method for determining degree of modified potency of a medicament

---

Salehi et al.2012|Simultaneous UV-VIS spectrophotometric determination of aspirin and methocarbamol in pharmaceutical preparations

---

WO2012017327A2|2012-02-09|Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv

同族专利:

---

公开号 | 公开日

---

KR20150133786A|2015-11-30|

---

UA117675C2|2018-09-10|

---

ES2560897R1|2016-03-29|

---

BR112015023917A2|2017-07-18|

---

GB2531169A|2016-04-13|

---

EP2976636A2|2016-01-27|

---

EA201500924A1|2016-04-29|

---

WO2014147487A3|2014-12-31|

---

GB201518061D0|2015-11-25|

---

AU2014233938A1|2015-10-15|

---

PE20151556A1|2015-11-05|

---

CA2907524A1|2014-09-25|

---

AR096018A1|2015-12-02|

---

EA030610B1|2018-08-31|

---

JP6527853B2|2019-06-05|

---

CN105209906A|2015-12-30|

---

JP2016516205A|2016-06-02|

---

CL2015002779A1|2016-10-07|

---

US20140287442A1|2014-09-25|

---

GB2531169B|2018-04-04|

---

MX2015013379A|2016-01-08|

---

US9945868B2|2018-04-17|

---

WO2014147487A2|2014-09-25|

---

RU2013111961A|2014-09-27|

---

DE112014001501T5|2016-04-14|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

IL125743A|1996-02-12|2003-09-17|Epshtein Oleg Iliich|Medicinal preparation containing an active medical substance with homeopathic potentiation|

---

RU2112976C1|1997-04-07|1998-06-10|Акционерное общество закрытого типа "Международный концерн "ЭДАС"|Method for determination of quality of homeopathic medicinal preparations and device for its realization|

---

RU2161955C1|1999-07-16|2001-01-20|Эпштейн Олег Ильич|Method of varying physico-chemical and biological properties of substance|

---

RU2181297C2|2000-06-20|2002-04-20|Эпштейн Олег Ильич|Method of treatment of pathological syndrome and medicinal agent|

---

RU2195648C2|2000-11-03|2002-12-27|Эпштейн Олег Ильич|Method of qualitative determination of homeopathic medicinal preparation or potentiated form of substance|

---

RU2192888C1|2001-02-15|2002-11-20|Эпштейн Олег Ильич|Medicinal agent and method of treatment of pathological syndrome|

---

RU2191601C1|2001-04-18|2002-10-27|Эпштейн Олег Ильич|Medicinal preparation and method for treating erectile dysfunctions|

---

RU2181890C1|2001-06-06|2002-04-27|Научно-исследовательский и учебно-методический центр биомедицинских технологий ВИЛАР|Method for selecting substances manifesting adaptogenic properties in vitro|

---

RU2201255C1|2001-12-26|2003-03-27|Эпштейн Олег Ильич|Medicinal agent and method of regulation of vascular tonus|

---

EP1547611A4|2002-08-02|2006-01-25|Oleg Iliich Epshtein|Medicinal agent and method for curing prostate diseases|

---

US20060153845A1|2002-08-02|2006-07-13|Epshtein Oleg I|Method for correcting immune respones and medical agent|

---

UA76638C2|2002-08-02|2006-08-15|Oleh Illich Epshtein|Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon|

---

US7700096B2|2002-08-02|2010-04-20|Oleg Iliich Epshtein|Medicinal agent for treating erectile dysfunction|

---

RU2253478C1|2003-10-01|2005-06-10|Эпштейн Олег Ильич|Agent for potentiation therapeutical effects: enhancing effect of drug|

---

RU2309732C1|2006-03-13|2007-11-10|Олег Ильич Эпштейн|Pressed solid oral formulation of medicinal preparation and method for preparing solid oral formulation of medicinal preparation|

---

CA2654408C|2006-06-06|2018-05-08|Oleg Iliich Epshtein|Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance|

---

RU2438707C2|2006-06-06|2012-01-10|Олег Ильич Эпштейн|Medication for per oral treatment of diabetes mellitus and other diseases accompanied by disturbance of tolerance to glucose, and method of obtaining hard drug form for per oral therapy of diabetes mellitus and other diseases, accompanied by disturbance of tolerance to glucose|

---

RU2332236C1|2007-02-02|2008-08-27|Олег Ильич Эпштейн|Medicine for bird influenza treatment|

---

US20130189707A1|2010-01-26|2013-07-25|Svetlana Alexandrovna Sergeeva|Method of determination of autoantibody level by means of enzyme immunoassay|

---

SG187035A1|2010-07-15|2013-02-28|Oleg Iliich Epshtein|Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract|

---

MY158183A|2010-07-15|2016-09-15|Epshtein Oleg Lliich|Pharmaceutical compositions and methods of treatment|

---

DE112011102358T5|2010-07-15|2013-04-25|Oleg Iliich Epshtein|A method of increasing the effect of an activated-potentiated form of an antibody|

---

FR2962655A1|2010-07-15|2012-01-20|Oleg Iliich Epshtein|PHARMACEUTICAL ASSOCIATION COMPOSITION AND USES THEREOF IN METHODS OF TREATMENT OF GENITAL URINARY SYSTEM DISORDERS|

---

EA201300128A1|2010-07-15|2013-12-30|Олег Ильич ЭПШТЕЙН|COMBINED PHARMACEUTICAL COMPOSITION AND METHODS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH DISABILITY OF THE CARDIOVASCULAR SYSTEM|

---

US8637034B2|2010-07-15|2014-01-28|Oleg I. Epshtein|Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein|

---

ITTO20110634A1|2010-07-21|2012-01-22|Oleg Iliich Epshtein|METHOD FOR TREATING ORGANIC DISEASES OF THE NERVOUS SYSTEM, THE PSYCHOORGANIC SYNDROME AND THE SYNTHALOPATHY|

---

EA029847B1|2010-07-21|2018-05-31|Олег Ильич ЭПШТЕЙН|Combination pharmaceutical composition and method of treating diabetes mellitus and associated metabolic disorders|

---

UA112755C2|2010-07-21|2016-10-25|Олєг Ільіч Епштейн|A method of treating attention deficit hyperactivity disorder|

---

EA029399B1|2010-07-21|2018-03-30|Олег Ильич ЭПШТЕЙН|Combination pharmaceutical composition for treating alzheimer's disease and method of treating alzheimer's disease|

---

FR2962909A1|2010-07-21|2012-01-27|Oleg Iliich Epshtein|PHARMACEUTICAL ASSOCIATION COMPOSITION AND ITS USE IN METHODS FOR TREATING DISEASES OR DISORDERS ASSOCIATED WITH RESPIRATORY DISEASE OR DISEASE|

---

EP2596018A2|2010-07-21|2013-05-29|Oleg Iliich Epshtein|Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia|

---

RU2517084C2|2010-08-06|2014-05-27|Олег Ильич Эпштейн|Method and means for inhibiting production or enhancing protein p24 elimination|

---

RU2535033C2|2010-08-06|2014-12-10|Олег Ильич Эпштейн|Therapeutic agent and method for prevention of hiv infection and treatment of hiv-caused or hiv-associated diseases, including aids|

---

CN103154030A|2010-08-06|2013-06-12|奥列格·伊里奇·爱泼斯坦|Combination pharmaceutical composition and methods of treating and preventing the infectious diseases|

---

RU2535034C2|2010-08-06|2014-12-10|Олег Ильич Эпштейн|Medication and method of preventing hiv infection, prevention and treatment of hiv-induced or hiv-associated diseases, including aids|

---

US20120263725A1|2010-08-06|2012-10-18|Epshtein Oleg Iiiich|Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV|

---

US20130171161A1|2010-12-23|2013-07-04|Oleg Iliich Epshtein|Method and composition for the treatment of diseases caused by or associated with hiv|

---

RU2013111961A|2013-03-18|2014-09-27|Олег Ильич Эпштейн|METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER|RU2013111962A|2013-03-18|2014-09-27|Олег Ильич Эпштейн|METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER|

---

RU2013111961A|2013-03-18|2014-09-27|Олег Ильич Эпштейн|METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER|

---

WO2017147616A1|2016-02-28|2017-08-31|Standard Homeopathic Company|Methods and compositions for using solvatochromic dyes to detect the presence of homeopathic potencies|

---

RU2679885C1|2018-05-31|2019-02-14|Александр Мордухаевич Клейман|Method of preparing homeopathic preparations based on organic compounds|

法律状态:
2017-05-22| FC2A| Grant refused|Effective date: 20170516 |

优先权:

---

申请号 | 申请日 | 专利标题

---

RU2013111961/15A|RU2013111961A|2013-03-18|2013-03-18|METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER|

---

RU2013111961|2013-03-18|

---